Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

TY - JOUR

T1 - Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis

AU - Ross, C

AU - Clemmesen, K M

AU - Sørensen, P S

AU - Koch-Henriksen, Nils

AU - Bendtzen, K

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P

AB - Administration of interferons (IFNs) may induce antibodies that interfere with therapeutic efficacy. We have optimized and validated methods for large-scale economic screening. Sera from patients with relapsing-remitting multiple sclerosis (MS) were investigated for binding antibody (BAb) by protein-G affinity-chromatography radioimmunoassay and a commercially available enzyme immunoassay (EIA). Neutralizing antibody (NAb) was investigated by cytopathic effect assays (CEA) using both fixed amount and serially diluted sera. BAb correlated with log10-transformed titres obtained by EIA (r=0.70, P

M3 - Journal article

SN - 1352-4585

VL - 12

SP - 39

EP - 46

JO - Multiple Sclerosis

JF - Multiple Sclerosis

IS - 1

ER -